Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia

PharmacoEconomics

Volumn 31, Issue 5, 2013, Pages 377-391

  Sorich, Michael J ^a   Wiese, Michael D ^a   O'Shea, Rebekah L ^b   Pekarsky, Brita ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KINESIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; ROSUVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; COST-BENEFIT ANALYSIS; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KINESIN; ORGANIC ANION TRANSPORTERS; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS;

EID: 84877997203     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0045-6     Document Type: Review

References (87)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-32.
2. National Center for Health Statistics. Health, United States, 2010: with special feature on death and dying [DHHS Publication No. 2011-1232]. Hyattsville: US Department of Health and Human Services; 2011.
3. Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS): expenditure and prescriptions twelve months to 30 June 2011. Canberra: Australian Government. 2012. http://www.health.gov.au/internet/main/publishing. nsf/content/pbs-stats-pbexp-jun11. Accessed 19 Aug 2012.
4. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff. 2009;28(1):w151-60.
5. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-818.
6. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
7. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
8. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
9. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129-35.
10. Mitsios JV, Papathanasiou AI, Goudevenos JA, et al. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des. 2010;16(34):3808-14.
11. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977-87.
12. Abela GS, Vedre A, Janoudi A, et al. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol. 2011;107(12):1710-7.
13. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108(4):426-31.
14. Superko HR, Momary KM, Li Y. Statins personalized. Med Clin N Am. 2012;96(1):123-39.
15. Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002;163(2):287-96.
16. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87(1):130-3.
17. Romaine SPR, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2010;10(1):1-11.
18. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: A Genomewide Study. N Engl J Med. 2008;359(8):789-99.
19. Kemp LK, Doran CM, Vos T, et al. Cost-effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease. Expert Rev Pharmacoecon Outcomes Res. 2007;7(2):119-28.
20. Maitland-van der Zee AH, Klungel OH, Stricker BHC, et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting [beta]-hydroxy-[beta]-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics. 2004;14(1):53-60.
21. Parthan A, Iakoubova O, Leahy K, et al. Cost effectiveness of targeted statin therapy following genotype testing among acute coronary syndrome patients [abstract no. 1538 plus poster]. 16th World Congress on Heart Disease; 23-26 July 2011; Vancouver.
22. Doggrell SA. The ezetimibe controversy: can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opin Pharmacother. 2012;13(10):1469-80.
23. Carlquist JF, Muhlestein JB, Horne BD, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J. 2003;146(6):1007-14.
24. Kakko S, Tamminen M, Päivänsalo M, et al. Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur J Clin Invest. 2001;31(7):593-602.
25. Arca M, Montali A, Ombres D, et al. Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clin Genet. 2001;60(5):374-80.
26. Eiriksdottir G, Bolla MK, Thorsson B, et al. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis. 2001;159(1):187-92.
27. Marschang P, Sandhofer A, Ritsch A, et al. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med. 2006;260(2):151-9.
28. Mohrschladt MF, Van der Sman-de Beer F, Hofman MK, et al. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet. 2005;13(7):877-82.
29. Kuivenhoven J, Jukema J, Zwinderman A, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338(2):86-93.
30. de Grooth GJ, Zerba KE, Huang SP, et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome - a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol. 2004;43(5):854-7.
31. Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J. 2003;24(20):1833-42.
32. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment. Circulation. 2005;111(3):278-87.
33. Dullaart RP, Sluiter WJ. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics. 2008;9(6):747-63.
34. Maitland-van der Zee AH, Stricker BHC, Klungela OH, et al. Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis. 2004;175(2):377-9.
35. Marian AJ, Safavi F, Ferlic L, et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the Lipoprotein and Coronary Atherosclerosis Study. J Am Coll Cardiol. 2000;35(1):89-95.
36. Bray PF, Cannon CP, Goldschmidt-Clermont P, et al. The platelet Pl (A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001;88:347-52.
37. Maitland-van der Zee A, Boerwinkle E, Arnett D, et al. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J. 2007;153(1):54-8.
38. Kitsios G, Zintzaras E. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet. 2009;10:50.
39. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504.
40. Iakoubova O, Sabatine M, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 Study. J Am Coll Cardiol. 2008;51(4):449-55.
41. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
42. Charland SL, Agatep BC, Schrader BJ, et al. Statin adherence in males and females, and the impact of knowledge of a genetic test: results from the AKROBATS Trial [abstract no. 290 plus poster]. Circ Cardiovasc Qual Outcomes. 2012;5:A290.
43. Assimes TL, Hólm H, Kathiresan S, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010;56(19):1552-63.
44. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008;51(4):435-43.
45. Iakoubova OA, Robertson M, Tong CH, et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil. 2010;17(4):455-61.
46. Shiffman D, Sabatine MS, Louie JZ, et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol. 2010;105(9):1300-5.
47. Hopewell JC, Parish S, Clarke R, et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the Heart Protection Study. J Am Coll Cardiol. 2011;57(20):2000-7.
48. Ridker PM, MacFadyen JG, Glynn RJ, et al. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ Cardiovasc Genet. 2011;4(3):312-7.
49. Hoffmann MM, Marz W, Genser B, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis. 2011;219(2):659-62.
50. Arsenault BJ, Boekholdt SM, Hovingh GK, et al. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012;5(1):51-7.
51. Marks D, Thorogood M, Neil HAW, et al. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J Public Health. 2003;25(1):47-52.
52. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ. 2002;324(7349):1303.
53. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med. 2004;4(1):97-104.
54. Marang-van de Mheen P, ten Asbroek A, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur Heart J. 2002;23(24):1922-30.
55. Oliva J, Lopez-Bastida J, Moreno SG, et al. Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia [in Spanish]. Rev Esp Cardiol. 2009;62(1):57-65.
56. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011;97(14):1175-81.
57. Minhas R, Humphries SE, Qureshi N, et al. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart. 2009;95(7):584-7.
58. Vergopoulos A, Knoblauch H, Schuster H. DNA testing for familial hypercholesterolemia: improving disease recognition and patient care. Am J Pharmacogenomics. 2002;2(4):253-62.
59. Humphries SE, Neil HAW. Developing and applying clinically useful approaches to identify individuals with familial hypercholesterolemia in the UK. Clin Lipidol. 2010;5(4):497-507.
60. Ioannidis J, Panagiotou O. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 2011;305(21):2200-10.
61. Ioannidis JPA, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29(3):306-9.
62. Bossuyt PM. The thin line between hope and hype in biomarker research. JAMA. 2011;305(21):2229-30.
63. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2(3):80-90.
64. Talameh JA, McLeod HL. PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication? Clin Pharmacol Ther. 2011;90(6):771-4.
65. US Food and Drug Administration. Guidance for industry: E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. Rockville: FDA. 2008. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073162.pdf. Accessed 14 Aug 2012.
66. Bailey KM, Romaine SP, Jackson BM, et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010;3(3):276-85.
67. Poduri A, Khullar M, Bahl A, et al. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol. 2010;29(10):629-37.
68. Maitland-van der Zee A-H, Lynch A, Boerwinkle E, et al. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics. 2008;18(8):651-6.
69. Chiodini BD, Franzosi MG, Barlera S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J. 2007;28(16):1977-83.
70. Kral A, Kovarnik T, Kralik L, et al. Genetic variants in haem oxygenase-1 and endothelial nitric oxide synthase influence the extent and evolution of coronary artery atherosclerosis. Folia Biol (Praha). 2011;57(5):182-90.
71. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21(5):280-8.
72. Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51(1):140-9.
73. Cerda A, Genvigir FDV, Willrich MAV, et al. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Lipids Health Dis. 2011;10:206.
74. Chien K-L, Wang K-C, Chen Y-C, et al. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010;11(3):309-17.
75. Hamrefors V, Orho-Melander M, Krauss RM, et al. A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. J Lipid Res. 2010;51(3):625-34.
76. Trompet S, de Craen AJM, Postmus I, et al. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco) genetic analyses. BMC Med Genet. 2011;12:131.
77. Baptista R, Rebelo M, Decq-Mota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis. 2011;10:48.
78. Davies NM, Windmeijer F, Martin RM, et al. Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle. Clin Chem. 2011;57(3):502-10.
79. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC Guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92:112-7.
80. US Food and Drug Administration. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Rockville: FDA. 2011. http://www.fda.gov/ Drugs/DrugSafety/ucm256581.htm. Accessed 19 Aug 2012.
81. Donnelly L, Doney A, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther. 2011;89(2):210-6.
82. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609-16.
83. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis. 2010;211(1):28-9.
84. Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012;12(3):233-7.
85. Teutsch SM, Bradley LA, Palomaki GE, et al. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med. 2009;11(1):3-14.
86. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(02):165-71.
87. Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov. 2009;8(4):279-86.